Sarah Kraus1,2, Simone Hummler3, Nadir Arber1,2, Cornelia M Ulrich3,4, Adetunji T Toriola5, Elizabeth M Poole4,6,7, Dominique Scherer3, Jana Kotzmann3, Karen W Makar4, Dina Kazanov1, Lior Galazan1,2, Inna Naumov1,2, Anna E Coghill4, David Duggan8, Biljana Gigic3. 1. Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3. National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Fred Hutchinson Cancer Research Center, Seattle, Washington. 5. Department of Surgery, Division of Public Health Sciences, Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri. 6. Department of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 7. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. 8. Translational Genomics Research Institute, Phoenix, Arizona, USA.
Abstract
OBJECTIVE: Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity. In this pilot study, we evaluated associations between genetic variation in several candidate pathways (e.g. prostaglandin synthesis) and adenoma recurrence and cardiovascular and gastrointestinal toxicities. METHODS: Genotyping analysis was carried out on 117 Israeli colorectal adenoma patients who participated in the Prevention of Colorectal Sporadic Adenomatous Polyps trial. Reassessment followed after 3 years on celecoxib and after 2 years from termination of treatment with celecoxib. Efficacy (absence of colorectal adenomas) was measured by colonoscopy at years 1, 3, and 5. Toxicities were assessed by investigators during celecoxib treatment and by self-report post-treatment. A linkage disequilibrium-based selection algorithm (r2≥0.90, MAF≥4%) identified 255 tagSNPs in 25 analyzed candidate genes. Genotyping was performed by using Illumina GoldenGate technology. RESULTS: Multiple genetic variants were associated with adenoma recurrence and toxicity. Genetic variability in COX1, COX2, and ALOX12/15 genes played a role in adenoma recurrence, particularly among patients on placebo. More gene variants (especially variants in PGES, CRP, SRC, and GPX3) were associated with increased risk for cardiovascular toxicity and symptoms, compared with gastrointestinal toxicity and symptoms. The increased risk for cardiovascular toxicity/symptoms associated with the SRC gene variants (rs6017996, rs6018256, rs6018257) ranged from 6.61 (95% confidence interval 1.66-26.36, P<0.01) to 10.71 (95% confidence interval 1.96-58.60, P<0.01). CONCLUSION: Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms. Larger studies validating these pharmacogenetic relationships are needed.
OBJECTIVE: Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity. In this pilot study, we evaluated associations between genetic variation in several candidate pathways (e.g. prostaglandin synthesis) and adenoma recurrence and cardiovascular and gastrointestinal toxicities. METHODS: Genotyping analysis was carried out on 117 Israeli colorectal adenomapatients who participated in the Prevention of Colorectal Sporadic Adenomatous Polyps trial. Reassessment followed after 3 years on celecoxib and after 2 years from termination of treatment with celecoxib. Efficacy (absence of colorectal adenomas) was measured by colonoscopy at years 1, 3, and 5. Toxicities were assessed by investigators during celecoxib treatment and by self-report post-treatment. A linkage disequilibrium-based selection algorithm (r2≥0.90, MAF≥4%) identified 255 tagSNPs in 25 analyzed candidate genes. Genotyping was performed by using Illumina GoldenGate technology. RESULTS: Multiple genetic variants were associated with adenoma recurrence and toxicity. Genetic variability in COX1, COX2, and ALOX12/15 genes played a role in adenoma recurrence, particularly among patients on placebo. More gene variants (especially variants in PGES, CRP, SRC, and GPX3) were associated with increased risk for cardiovascular toxicity and symptoms, compared with gastrointestinal toxicity and symptoms. The increased risk for cardiovascular toxicity/symptoms associated with the SRC gene variants (rs6017996, rs6018256, rs6018257) ranged from 6.61 (95% confidence interval 1.66-26.36, P<0.01) to 10.71 (95% confidence interval 1.96-58.60, P<0.01). CONCLUSION: Genetic polymorphisms in multiple inflammation-related genes appear to interact with celecoxib on adenoma recurrence and its attendant toxicity, particularly cardiovascular toxicity/symptoms. Larger studies validating these pharmacogenetic relationships are needed.
Authors: Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron Journal: N Engl J Med Date: 2005-02-15 Impact factor: 91.245
Authors: Elizabeth M Poole; Jeannette Bigler; John Whitton; Justin G Sibert; Richard J Kulmacz; John D Potter; Cornelia M Ulrich Journal: Carcinogenesis Date: 2007-02-02 Impact factor: 4.944
Authors: Cornelia M Ulrich; Jeannette Bigler; Justin Sibert; Elizabeth A Greene; Rachel Sparks; Christopher S Carlson; John D Potter Journal: Hum Mutat Date: 2002-11 Impact factor: 4.878
Authors: Jason A Zell; Christine E McLaren; Wen-Pin Chen; Patricia A Thompson; Eugene W Gerner; Frank L Meyskens Journal: J Natl Cancer Inst Date: 2010-08-26 Impact factor: 13.506
Authors: John A Baron; Robert S Sandler; Robert S Bresalier; Angel Lanas; Dion G Morton; Robert Riddell; Erik R Iverson; David L Demets Journal: Lancet Date: 2008-10-14 Impact factor: 79.321
Authors: Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Aurora Breazna; Kyungmann Kim; Jie Tang; Rebecca B Rosenstein; Asad Umar; Donya Bagheri; Neal T Collins; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Ernest T Hawk Journal: Cancer Prev Res (Phila) Date: 2009-03-31
Authors: Dominique Scherer; Lisel M Koepl; Elizabeth M Poole; Yesilda Balavarca; Liren Xiao; John A Baron; Li Hsu; Anna E Coghill; Peter T Campbell; Sarah E Kleinstein; Jane C Figueiredo; Johanna W Lampe; Katharina Buck; John D Potter; Richard J Kulmacz; Mark A Jenkins; John L Hopper; Aung K Win; Polly A Newcomb; Cornelia M Ulrich; Karen W Makar Journal: Genes Chromosomes Cancer Date: 2014-03-28 Impact factor: 5.006
Authors: Harsh Sheth; Emma Northwood; Cornelia M Ulrich; Dominique Scherer; Faye Elliott; Jennifer H Barrett; David Forman; C Roland Wolf; Gillian Smith; Michael S Jackson; Mauro Santibanez-Koref; Robert Haile; Graham Casey; Mark Jenkins; Aung Ko Win; John L Hopper; Loic Le Marchand; Noralane M Lindor; Stephen N Thibodeau; John D Potter; John Burn; D Timothy Bishop Journal: PLoS One Date: 2018-02-09 Impact factor: 3.240